Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 6/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014930 | 1.00 | ACLY (0.51) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL15295148 | 0.94 | ACLY (0.45) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL16675380 | 0.94 | ACLY (0.45) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL16675398 | 0.93 | ACLY (0.46) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL15295224 | 0.93 | ACLY (0.46) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL15287441 | 0.91 | ACLY (0.44) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL2923778 | 0.91 | ACLY (0.45) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL2924748 | 0.91 | ACLY (0.45) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL2930161 | 0.91 | ACLY (0.55) | ACLYPTGDR2DRD4EPHA2KDR | |
| SCHEMBL2928718 | 0.91 | ACLY (0.55) | ACLYPTGDR2DRD4EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | ACLY 3558/4885PTGDR2 1665/4885DRD4 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.